Autopsy report · NCT03641703

A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Freeline has decided to pause development of FLT180a for business priorities”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 4 years 10 months before it stopped.
10 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: Spur Therapeutics
Sponsor type: Industry
Conditions: Hemophilia B
Interventions: FLT180a
Participants: 10
Sites: 6
Countries: United Kingdom

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.